Tvardi Therapeutics (TVRD) Raw Materials (2021 - 2022)

Tvardi Therapeutics (TVRD) posted Raw Materials of $1.8 million for Q3 2022, up 0.71% sequentially from $1.8 million in Q2 2022.

Tvardi Therapeutics (TVRD) Raw Materials (2021 - 2022) Analysis & Trends

Tvardi Therapeutics has reported Raw Materials for 2 years, with the latest figure at $1.8 million in Q3 2022.

Quarterly Raw Materials changed N/A year-over-year to $1.8 million in Q3 2022, while the trailing twelve-month figure through Sep 2022 was $1.8 million (changed N/A YoY) and the FY2021 annual result came in at $927000.0, changed N/A from the prior year.
Raw Materials climbed to $1.8 million in Q3 2022 per TVRD's latest filing, from $1.8 million in the prior quarter.
Over five years, Raw Materials peaked at $1.8 million in Q3 2022 and troughed at $927000.0 in Q4 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Tvardi Therapeutics	17.36 Mn	17.36 Mn	-

Download Data